Sec Form 3 Filing - Stock Elyse @ Biohaven Pharmaceutical Holding Co Ltd. - 2019-08-08

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Stock Elyse 2. Issuer Name and Ticker or Trading Symbol Biohaven Pharmaceutical Holding Co Ltd. [ BHVN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Medical Officer (Last) (First) (Middle) C/O BIOHAVEN PHARMACEUTICALS, INC., 215 CHURCH STREET 3. Date of Earliest Transaction (MM/DD/YY) 08/08/2019 (Street) NEW HAVEN, CT06510 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (Right to Buy) $ 10.82 ( 1 ) 04/05/2027 Common Shares 37,000 D Employee Stock Option (Right to Buy) $ 37.54 ( 2 ) 09/04/2027 Common Shares 10,000 D Employee Stock Option (Right to Buy) $ 20.79 ( 3 ) 12/06/2027 Common Shares 42,612 D Employee Stock Option (Right to Buy) $ 32.42 ( 4 ) 11/20/2028 Common Shares 65,000 D Employee Stock Option (Right to Buy) $ 50.85 ( 5 ) 03/22/2029 Common Shares 6,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Stock Elyse C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN, CT06510 Chief Medical Officer Signatures /s/ James Engelhart, Attorney-in-fact 08/19/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The option became exercisable as to 18,500 of these shares on and prior to April 6, 2019 and becomes exercisable as to the remaining 18,500 shares on April 6, 2020, subject to the reporting person's continued service as of such date. ( 2 )The option became exercisable as to 2,500 of these shares on September 5, 2018, with the remainder vesting in 3 equal installments on September 5, 2019, September 5, 2020 and September 5, 2021, subject to the reporting person's continuing service as of each applicable vesting date. ( 3 )The option became exercisable as to 10,653 of these shares on December 7, 2018, with the remainder vesting in 3 equal installments on December 7, 2019, December 7, 2020 and December 7, 2021, subject to the reporting person's continuing service as of each applicable vesting date. ( 4 )The option vests in 4 equal installments on the first, second, third and fourth anniversaries of November 20, 2018, in each case subject to the reporting person's continuing service as of each applicable vesting date. ( 5 )This option vested as to all 6,000 shares on June 27, 2019.

Remarks: Exhibit 24.1 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.